{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:53:03Z","timestamp":1772121183881,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To systematically evaluate the efficacy and safety of albumin-bound paclitaxel and paclitaxel in the treatment of esophageal cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Seven databases (PubMed, Cochrane Library, Embase, China National Knowledge Infrastructure, Wanfang Data, China Science and Technology Journal Database, and China Biology Medicine disc) were searched for randomized controlled trials (RCTs) of albumin-bound paclitaxel and paclitaxel in the treatment of esophageal cancer. The search was conducted from database inception to February 2025. Literature quality was assessed using the Cochrane Risk of Bias Tool version 1 (RoB 1), and the systematic review and meta-analysis was performed using RevMan 5.4.1 and STATA18.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eleven RCTs were included. Meta-analysis demonstrated that albumin-bound paclitaxel significantly improved objective response rate [ORR; relative risk (RR) = 1.67, 95% confidence interval (CI) [1.45, 1.92], p &amp;lt; 0.001, I<jats:sup>2<\/jats:sup> = 0%] and disease control rate (DCR; RR = 1.69, 95% CI [1.43, 1.98], p &amp;lt; 0.001, I<jats:sup>2<\/jats:sup> = 0%) compared to paclitaxel. It also showed superior improvements in serum tumor markers: cancer antigen 125 (CA125) [mean difference (MD) = \u22121.69, 95% CI [\u22122.73, \u22120.65], p &amp;lt; 0.001, I<jats:sup>2<\/jats:sup> = 83%], Carbohydrate antigen 19-9 (CA199) (MD = \u22122.12, 95% CI [\u22123.39, \u22120.84], p = 0.001, I<jats:sup>2<\/jats:sup> = 85%), and carcinoembryonic antigen (CEA) (MD = \u22122.01, 95% CI [\u22122.53, \u22121.50], p &amp;lt; 0.001, I<jats:sup>2<\/jats:sup> = 99%), although Squamous Cell Carcinoma Antigen (SCC) improvement was non-significant (MD = \u22121.19, 95% CI [\u22122.61, 0.24], p &amp;gt; 0.001, I<jats:sup>2<\/jats:sup> = 100%). Regarding safety, albumin-bound paclitaxel had markedly lower incidences of diarrhea (RR = 0.49, 95% CI [0.33, 0.72], p = 0.003, I<jats:sup>2<\/jats:sup> = 0%), nausea\/vomiting (RR = 0.61, 95% CI [0.46, 0.80], p &amp;lt; 0.001, I<jats:sup>2<\/jats:sup> = 0%), thrombocytopenia (RR = 0.61, 95% CI [0.44, 0.85], p = 0.004, I<jats:sup>2<\/jats:sup> = 22%), and myalgia\/arthralgia (RR = 0.45, 95% CI [0.22, 0.94], p = 0.03, I<jats:sup>2<\/jats:sup> = 0%), while neutropenia showed no significant difference (RR = 0.58, 95% CI [0.32, 1.03], p = 0.006, I<jats:sup>2<\/jats:sup> = 0%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Compared to paclitaxel, albumin-bound paclitaxel (nab-paclitaxel) demonstrates superior efficacy in the treatment of esophageal cancer, with fewer adverse reactions such as diarrhea, thrombocytopenia, and musculoskeletal pain.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1612678","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T04:10:16Z","timestamp":1755490216000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of albumin-bound paclitaxel versus paclitaxel in esophageal cancer: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Jiayang","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongfu","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nanjiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s10388-022-00936-3","article-title":"Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil\/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinoma","volume":"19","author":"Ito","year":"2022","journal-title":"Esophagus"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15884","article-title":"Additional effects of docetaxel on neoadjuvant radiotherapy with cisplatin\/5-fluorouracil for esophageal squamous cell carcinoma","volume":"42","author":"Sasaki","year":"2022","journal-title":"Anticancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2006.02.027","article-title":"A folate receptor-targeted liposomal formulation for paclitaxel","volume":"316","author":"Wu","year":"2006","journal-title":"Int J Pharmaceut"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2007.06.051","article-title":"Safety and efficacy of amphiphilic \u03b2-cyclodextrin nanoparticles for paclitaxel delivery","volume":"347","author":"Bilensoy","year":"2008","journal-title":"Int J Pharmaceut"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2004.12.009","article-title":"Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery","volume":"103","author":"Soga","year":"2005","journal-title":"J Controlled Release"},{"key":"B8","doi-asserted-by":"publisher","first-page":"93","DOI":"10.14146\/j.cnki.cjp.2023.02.005","article-title":"Research progress of nanobioalbumin-bound paclitaxel in tumor therapy","volume":"21","author":"Cao","year":"2023","journal-title":"Chin J Pharmaceut"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J @ Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ-British Med J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-022-0949-7","article-title":"GDF15 negatively regulates chemosensitivity via TGFBR2-AKT pathway-dependent metabolism in esophageal squamous cell carcinoma","volume":"17","author":"Du","year":"2023","journal-title":"Front Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.13455\/j.cnki.cjcor.2021.08.08","article-title":"Efficacy of albumin-bound paclitaxel combined with radiotherapy for esophageal cancer","volume":"28","author":"Dang","year":"2021","journal-title":"Chin J Clin Oncol Rehabil"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.13501\/j.cnki.42-1590\/r.2022.02.024","article-title":"The effect of albumin-bound paclitaxel combined with nedaplatin on esophageal cancer and its impact on 3-year survival rate and toxicity","volume":"39","author":"Zhao","year":"2022","journal-title":"J Hubei Minzu University\u00b7Med Edition"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.14164\/j.cnki.cn11-5581\/r.2024.03.008","article-title":"Clinical effect analysis of albumin-binding paclitaxel combined with nedaplatin in the treatment ofadvanced esophageal cancer","volume":"18","author":"Xing","year":"2024","journal-title":"Chin J Mod Drug App"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.19368\/j.cnki.2096-1782.2019.23.118","article-title":"Clinical analysis of albumin-bound paclitaxel combined with cisplatinin the treatment of patients with advanced esophageal cancer","volume":"4","author":"Jiang","year":"2019","journal-title":"Syst Med"},{"key":"B17","first-page":"49","article-title":"Clinical efficacy observation of albumin-bound paclitaxel combined with cisplatin chemotherapy in the treatment of advanced esophageal cancer","volume":"10","author":"Tu","year":"2020","journal-title":"Med Front"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1004-5775.2020.10.021","article-title":"Study on the effect of abraxane and cisplatin in the treatment of advanced esophageal cancer","volume":"44","author":"Ren","year":"2020","journal-title":"Heilongjiang Med J"},{"key":"B19","article-title":"Value analysis of albumin-bound paclitaxel in neoadjuvant chemotherapy for locally advanced esophageal cancer","volume":"7","author":"Zhong","year":"2022","journal-title":"Big Doctor"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.14163\/j.cnki.11-5547\/r.2024.15.004","article-title":"Analysis of clinical effect of albumin-bound paclitaxel combined with radiotherapy in the treatment of esophageal cancer","volume":"19","author":"Sha","year":"2024","journal-title":"China Prac Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.14164\/j.cnki.cn11-5581\/r.2019.22.066","article-title":"Analysis of of albumin-bound paclitaxel in the treatment of advanced esophageal cancer","volume":"13","author":"Yan","year":"2019","journal-title":"Chin J Mod Drug App"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-8351.2024.09.059","article-title":"The effect of netafop combined with albumin-binding paclitaxel on advanced esophageal cancer and tts impact on serum tumor markers","volume":"21","author":"Wu","year":"2024","journal-title":"Northern Pharmaceut"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1672-8351.2023.08.040","article-title":"A study on the clinical efficacy of albumin-bound paclitaxel combined with nedaplatin in treating advanced esophageal cancer","volume":"20","author":"Chen","year":"2023","journal-title":"Northern Pharmaceut"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.16073\/j.cnki.cjcpt.2024.22.08","article-title":"Research progress in esophageal cancer screening. Chinese","volume":"31","author":"Zhu","year":"2024","journal-title":"Chin J Cancer Prev Treat"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1612678\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T04:10:26Z","timestamp":1755490226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1612678\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":24,"alternative-id":["10.3389\/fonc.2025.1612678"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1612678","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"article-number":"1612678"}}